Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 1.00 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.70 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.70 |
| ▸ | F10 | P00742 | 3/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.57 |
| ▸ | CDC25B | P30305 | 1/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kaurenoic Acid SCHEMBL29626999 | 1.00 | PTPN1 (1.00) | PTPN1HSD11B1HSD11B2F10PTPN2 | |
| Kaurenoic Acid SCHEMBL3489848 | 1.00 | PTPN1 (1.00) | PTPN1HSD11B1HSD11B2F10PTPN2 | |
| Kaurenoic Acid SCHEMBL266944 | 1.00 | PTPN1 (1.00) | PTPN1HSD11B1HSD11B2F10PTPN2 | |
| Kaurenoic Acid SCHEMBL31238213 | 1.00 | PTPN1 (1.00) | PTPN1HSD11B1HSD11B2F10PTPN2 | |
| Kaurenoic Acid SCHEMBL13401813 | 1.00 | PTPN1 (1.00) | PTPN1HSD11B1HSD11B2F10PTPN2 | |
| Kaurenoic Acid SCHEMBL13464128 | 1.00 | PTPN1 (1.00) | PTPN1HSD11B1HSD11B2F10PTPN2 | |
| Kaurenoic Acid SCHEMBL1921625 | 1.00 | PTPN1 (1.00) | PTPN1HSD11B1HSD11B2F10PTPN2 | |
| Kaurenoic Acid SCHEMBL18073589 | 1.00 | PTPN1 (1.00) | PTPN1HSD11B1HSD11B2F10PTPN2 | |
| Kaurenoic Acid SCHEMBL262426 | 1.00 | PTPN1 (1.00) | PTPN1HSD11B1HSD11B2F10PTPN2 | |
| Kaurenoic Acid SCHEMBL21803663 | 1.00 | PTPN1 (1.00) | PTPN1HSD11B1HSD11B2F10PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4175484-B1 | FLAVOR COMPOSITIONS FOR BEVERAGE AND PERSONAL CARE APPLICATIONS | FIRMENICH & CIE (CH) | 2024-12-04 | — | — | EP | claimed |
| US-20230413878-A1 | FLAVOR COMPOSITIONS FOR BEVERAGE AND PERSONAL CARE APPLICATIONS | FIRMENICH SA (CH) | 2023-12-28 | — | — | US | claimed |
| EP-4175484-A1 | FLAVOR COMPOSITIONS FOR BEVERAGE AND PERSONAL CARE APPLICATIONS | Firmenich SA (CH) | 2023-05-10 | — | — | EP | claimed |
| WO-2022129000-A1 | FLAVOR COMPOSITIONS FOR BEVERAGE AND PERSONAL CARE APPLICATIONS | FIRMENICH SA (CH) | 2022-06-23 | — | — | WO | claimed |
| EP-2155769-B1 | TISSUE DEGENERATION PROTECTION | UNIV LEUVEN KATH (BE) | 2012-06-27 | — | — | EP | claimed |
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | GEUNS JOANNES | 2010-04-22 | — | — | US | claimed |
| EP-2155769-A2 | TISSUE DEGENERATION PROTECTION | Katholieke Universiteit Leuven (BE) | 2010-02-24 | — | — | EP | claimed |
| WO-2008134828-A2 | TISSUE DEGENERATION PROTECTION | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2008-11-13 | — | — | WO | claimed |
| US-12446605-B2 | Sweeteners | SWEEGEN, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4175484-B1 | FLAVOR COMPOSITIONS FOR BEVERAGE AND PERSONAL CARE APPLICATIONS | FIRMENICH & CIE (CH) | 2024-12-04 | — | — | EP | disclosed |
| US-20230413878-A1 | FLAVOR COMPOSITIONS FOR BEVERAGE AND PERSONAL CARE APPLICATIONS | FIRMENICH SA (CH) | 2023-12-28 | — | — | US | disclosed |
| US-20230345984-A1 | SWEETENERS | Sweegen,Inc (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230279459-A1 | METHODS FOR IMPROVED PRODUCTION OF REBAUDIOSIDE D AND REBAUDIOSIDE M | DANSTAR FERMENT AG (CH) | 2023-09-07 | — | — | US | disclosed |
| EP-4175484-A1 | FLAVOR COMPOSITIONS FOR BEVERAGE AND PERSONAL CARE APPLICATIONS | Firmenich SA (CH) | 2023-05-10 | — | — | EP | disclosed |
| WO-2002060419-A2 | A SUBSTANCE FOR USE IN A DIETARY SUPPLEMENT OR FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERTENSION AND/OR THE METABOLIC SYNDROME | NUTRI PHARMA ASA (NO) | 2002-08-08 | — | — | WO | disclosed |
| US-6365768-B1 | DERIVATIVES OF ACANTHOIC AND KAURANOIC ACID; TREATMENT OF CACHEXIA' CARDIOVASCULAR DISEASE, OTITIS MEDIA, SINUSITIS AND TRANSPLANT; ANTI-INFLAMMATORY, DIABETIC AND CANCER AGENTS | NEREUS PHARMACEUTICALS, INC. | 2002-04-02 | — | — | US | disclosed |
| EP-1178952-A1 | NOVEL INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-$g(a) MODULATORS, SYNTHESES OF SAID MODULATORS AND METHODS OF USING SAID MODULATORS | Nereus Pharmaceuticals, Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2001056959-A1 | A SUBSTANCE FOR THE USE IN A DIETARY SUPPLEMENTATION OR FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERTENSION AND/OR THE METABOLIC SYNDROME | STEVIA APS (DK) | 2001-08-09 | — | — | WO | disclosed |
| WO-2000073253-A1 | NOVEL INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-α MODULATORS, SYNTHESES OF SAID MODULATORS AND METHODS OF USING SAID MODULATORS | NEREUS PHARMACEUTICALS, INC. (US) | 2000-12-07 | — | — | WO | disclosed |
| US-5229419-A | Anticarcinogenic agents | PURDUE RESEARCH FOUNDATION (US) | 1993-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | SORD, CASP3, TXNRD2 | PTPN1 3492/4885HSD11B1 187/4885HSD11B2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.